Asset Details
Do you wish to reserve the book?
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Do you wish to request the book?
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
2006
Overview
In this multicenter, placebo-controlled, randomized trial of postmenopausal women at high risk for a coronary event, raloxifene had no significant effect on the risk of primary coronary events, reduced the risk of invasive breast cancer and vertebral fractures, and increased the risk of fatal stroke and venous thromboembolism. A decision whether to use raloxifene for the prevention of breast cancer or vertebral fractures should be individualized, weighing benefits against potential risks.
In postmenopausal women at high risk for a coronary event, raloxifene had no significant effect on the risk of primary coronary events, reduced the risk of invasive breast cancer and vertebral fractures, and increased the risk of fatal stroke and venous thromboembolism.
Raloxifene is a nonsteroidal selective estrogen-receptor modulator (SERM) that binds to the estrogen receptor, leading to estrogen-agonist effects in some tissues and estrogen-antagonist effects in others.
1
Raloxifene therapy has been associated with improvement in the levels of serum lipoprotein cholesterol,
2
,
3
fibrinogen,
3
and homocysteine.
4
The favorable effect of raloxifene on markers of cardiovascular risk, coupled with evidence from observational studies that treatment with estrogen was associated with a reduced risk of coronary heart disease (CHD) in postmenopausal women,
5
,
6
led to the design of the Raloxifene Use for The Heart (RUTH) trial to determine the effect of raloxifene on clinical . . .
Publisher
Massachusetts Medical Society
Subject
/ Biological and medical sciences
/ Breast Neoplasms - epidemiology
/ Coronary Disease - epidemiology
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Raloxifene Hydrochloride - adverse effects
/ Raloxifene Hydrochloride - therapeutic use
/ Risk
/ Selective Estrogen Receptor Modulators - adverse effects
/ Selective Estrogen Receptor Modulators - therapeutic use
/ Spinal Fractures - epidemiology
/ Thromboembolism - epidemiology
/ Tumors
